参考文献/References:
[1] ZHANG Y P,WANG P,LI X,et al.GABC:a comprehensive resource and genome atlas for breast cancer[J].Int J Cancer,2020,148(4):988-994.
[2] 刘静,钟玲,陈庆秋,等.乳腺癌发生过程中ER、PR、HER-2及WT1蛋白表达变化的研究[J].临床肿瘤学杂志,2019,24(8):722-726.
LIU J,ZHONG L,CHEN Q Q,et al.Changes of ER,PR,HER-2 and WT1 protein expression during the development of breast cancer[J].Chin Clin Oncol,2019,24(8):722-726.
[3] DACKUS G M H E,JWIAK K,WALL E V D,et al.Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer[J].Breast Cancer Res Treat,2020,185(3):817-830.
[4] MASTRO L D,LAURENTIIS M D.Clinical applications of trastuzumab in the management of HER-2-positive breast cancer[J].Recent Prog Med,2019,110(12):594-603.
[5] 肖聪,张懿敏,孙圣荣.曲妥珠单抗联合CAF化疗治疗晚期乳腺癌临床效果观察[J].临床军医杂志,2019,47(4):368-370,374.
XIAO C,ZHANG Y M,SUN S R.The effect of trastuzumab combined with chemotherapy on the treatment of advanced breast cancer[J].Clin J Med Offic,2019,47(4):368-370,374.
[6] KRIDIS W B,SGHAIER S,CHARFEDDINE S,et al.A prospective study about trastuzumab-induced cardiotoxicity in HER2-positive breast cancer[J].Am J Clin Oncol,2020,43(7):510-516.
[7] NISHINO M,JACKMAN D M,HATABU H,et al.New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer:comparison with original RECIST and impact on assessment of tumor response to targeted therapy[J].AJR Am J Roentgenol,2010,195(3):221-228.
[8] BASCH E,IASONOS A,MCDONOUGH T,et al.Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events:results of a questionnaire-based study[J].Lancet Oncol,2006,7(11):903-909.
[9] 中国乳腺癌新辅助治疗专家组.中国乳腺癌新辅助治疗专家共识(2019年版)[J].中国癌症杂志,2019,29(5):390-400.
CHINA BREAST CANCER NEOADJUVANT THERAPY EXPERT GROUP.Expert consensus on neoadjuvant therapy for breast cancer in China (2019 Edition)[J].Chin Oncol,2019,29(5):390-400.
[10] WANG L,ASIRVATHAM J R,MA Y L,et al.HER-2/neu-positive breast cancer neoadjuvant chemotherapy response after implementation of 2018 ASCO/CAP focused update[J].Breast,2021,27(8):631-637.
[11] LIU X,ZHENG D,WU Y Q,et al.Treatment patterns and outcomes in older women with early breast cancer:a population-based cohort study in China[J].BMC Cancer,2021,21(1):226.
[12] SCHMID P,CHUI S Y,EMENS L A,et al.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J].N Engl J Med,2019,380(10):987-988.
[13] KASHIO-YOKOTA Y,SATO S,HIROSE T,et al.Elevated (pro)renin receptor expression by anti-cancer drugs,carboplatin and paclitaxel,in cultured cancer cells:possible involvement of apoptosis and autophagy[J].Tohoku J Exp Med,2021,255(2):91-104.
[14] CHUNG Y C,CHIU H H,WEI W C,et al.Application of trastuzumab emtansine in HER-2-positive and KRAS/BRAF-mutated colon cancer cells[J].Eur J Clin Invest,2020,50(8):e13255.
[15] 张婷,刘起鹏,郭婉莹,等.曲妥珠单抗联合术前新辅助化学治疗对乳腺癌患者肿瘤标志物、血管内皮因子和凋亡因子的影响及疗效观察[J].新乡医学院学报,2020,37(11):1075-1079.
ZHANG T,LIU Q P,GUO W Y,et al.Effect of trastuzumab combined with neoadjuvant chemotherapy on tumor markers,vascular en-dothelial growth factor and apoptotic factors in patients with breast cancer and therapeutic effect analysis[J].J Xinxiang Med Univ,2020,37 (11):1075-1079.
[16] KOLBERG H C,COLLEONI M,DEMETRIOU G S,et al.Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the randomized,double-blind,active-controlled LILAC study[J].Drug Safety,2020,43(3):233-242.
[17] NACK E,KOFFER P P,BLUMBERG C S,et al.New cardiac abnormalities after radiotherapy in breast cancer patients treated with trastuzumab[J].Clin Breast Cancer,2020,20(3):246-252.
[18] 黄剑全,苏新辉,余李娟,等.心肌摄取99Tcm-MIBI相对定量值和血清cTnI检测对蒽环类化疗药物心脏毒性的预测价值[J].标记免疫分析与临床,2019,26(10):1642-1645.
HUANG J Q,SU X H,YU L J,et al.The predictive values of cTnI and myocardial relative quantity of 99Tcm-MIBI for monitoring the anthracycline cardiotoxicity[J].Lab Immun Clin Med,2019,26 (10):1642-1645.
[19] TZOLOS E,ADAMSON P D,HALL P S,et al.Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy[J].Clin Oncol,2019,32(5):292-297.
[20] SULAIMAN L,HESHAM D,HAMID M A,et al.The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients[J].Egypt Heart J,2021,73(1):20.
相似文献/References:
[1]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[2]刘玉生 . 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[3]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[4]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[5]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[6]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[7]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[8]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.
[9]王 乐,王静萱,张清媛.乳腺癌骨转移靶向治疗进展[J].新乡医学院学报,2015,32(09):887.
[10]杨绍英,刘朝荣,张志刚,等.乳腺癌新辅助化学治疗前后雌激素受体、乳激素受体、Ki-67抗原和人类表皮生长因子受体-2的表达[J].新乡医学院学报,2017,34(2):125.[doi:10.7683/xxyxyxb.2017.02.012]
YANG Shao-ying,LIU Chao-rong,ZHANG Zhi-gang,et al.Expressions of estrogen receptor,progestin recetor,Ki-67 antigen,and human epidermal growth factor receptor 2 before and after neoadjuvant chemotherapy in patients with breast cancer[J].Journal of Xinxiang Medical University,2017,34(4):125.[doi:10.7683/xxyxyxb.2017.02.012]
[11]张 婷,刘起鹏,郭婉莹,等.曲妥珠单抗联合术前新辅助化学治疗对乳腺癌患者肿瘤标志物、血管内皮因子和凋亡因子的影响及疗效观察[J].新乡医学院学报,2020,37(11):1075.[doi:10.7683/xxyxyxb.2020.11.016]
ZHANG Ting,LIU Qipeng,GUO Wanying,et al.Effect of trastuzumab combined with neoadjuvant chemotherapy on tumor markers,vascular endothelial growth factor and apoptotic factors in patients with breast cancer and therapeutic effect analysis[J].Journal of Xinxiang Medical University,2020,37(4):1075.[doi:10.7683/xxyxyxb.2020.11.016]
[12]杨金伟,马楠楠,屈重阳,等.曲妥珠单抗对人表皮生长因子受体-2阳性乳腺癌患者的心血管毒性研究进展[J].新乡医学院学报,2022,39(4):396.[doi:10.7683/xxyxyxb.2022.04.020]
YANG Jinwei,MA Nannan,QU Chongyang,et al.Research progress on cardiovascular toxicity of trastuzumab in patients with human epidermal growth factor receptor-2 positive breast cancer[J].Journal of Xinxiang Medical University,2022,39(4):396.[doi:10.7683/xxyxyxb.2022.04.020]